BioAdvance

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Retinapharma Technologies, Inc., is a development stage biotechnology company seeking to develop potential products for the prevention, treatment and diagnosis of vision disorders and eye diseases. Retinapharma is a developer of a range of ophthalmic pharmaceuticals, devices, and consumer eye-care products. Retinapharma Technologies is focused on prevention, diagnosis, and treatment of blinding vision disorders, including early and late-stage age-related macular degeneration, glaucoma, retinitis pigmentosa, and diabetic retinopathy.

Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

SonoMedix engages in the development and commercialization of technology designed for monitoring blood coagulation and hemostatic status. The company offers Nano-Acoustic Blood Analyzer platform (NABA) technology that helps to interrogate and detect blood properties at the molecular level. This product enables healthcare workers and patients to conduct diagnostic and therapeutic monitoring at the bedside and at home, using a small hand-held device.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Innovative Supply Solutions LLC, a specialty contract service organization, provides clinical drug supply chain management services. Its services include planning/forecasting for API/formulated product needs, project management, budget projection/management, packaging design, inventory management, supply chain coordination and management, IVR/IWR supply design and management, manufacturing coordination, packaging and labeling coordination, distribution coordination, analytical services coordination, product sourcing, material destruction coordination, and consultancy. The company is based in Southampton, Pennsylvania.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

NexusPharma is dedicated to the discovery of novel anti-cancer treatments. Novel drug candidates are tested in patient derived xenograft tumor models or patient derived tumor cell lines that are derived from such PDX models – we are creating these models to reflect human disease in the most predictable ways. Please ask us if we could help you in your dicsovery projects with these technologies – creating drug candidates wit a higher chance of success in clinical trials.

VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

LumenVu, Inc., a privately held, development stage company based in Philadelphia.

Vindico Medical Education is an accredited provider of CME, CE, and CNE multiplatform activities, offering the highest quality continuing education with the ultimate goal of improving patient health. Vindico facilitates accredited activities that positively affect clinical practice and provides quality initiatives for improving knowledge, competence, performance, and patient health. Vindico is solely dedicated to creating educational activities that provide healthcare professionals with evidence-based education on clinical advances to improve their competence, performance-in-practice, and ultimately to better treat their patients. Vindico provides scientifically sound and evidence-based activities in a variety of core therapeutic areas including cardiology, endocrinology, hematology/oncology, infectious diseases, ophthalmology, orthopedics, and pediatrics. Vindico employs an experienced team of physicians, scientists, educators, medical writers and editors, dedicated meeting managers, and an in-house design and recruitment department that ensure a seamless process from activity planning through delivery.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

Relmada is a clinical-stage pain management company with a diversified portfolio of products for the treatment of chronic pain. It specializes in analgesic Drug Development, Chronic Pain, Pharmaceutical Development, and Opioid Addiction. The company was founded in 2004 and headquartered in Pennsylvania, United States.

Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Leversense, LLC intends to develop a medical device for detecting AIDS, food toxin, and mycoplasma bacteria. The company was incorporated in 2009 and is based in Newtown Square, Pennsylvania.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Midway Pharmaceuticals is a developer of specialty drugs designed to provide beneficial effects in the treatment of gastrointestinal and systemic diseases. The company's specialty drugs focus on finding high molecular weight polymers that can be consumed orally and inhibit the pathogenic behavior of bacteria in the GI tract, enhance gut barrier function and promote gastrointestinal healing, enabling healthcare institutions to avail enhanced drugs to protect people's guts from radiation damage and infection.

Anakim Biologics is developing efficiencies and improvements in biologics manufacturing;

Formae, Inc. develops products in arthroscopic joint resurfacing and replacement. It offers ArthroPad, a biocompatible implant offering an arthroscopic minimally invasive surgical option to replace damaged cartilage in arthritic joints. The company serves applications, such as arthritis and joint destructions. Formae, Inc. was founded in 2006 and is based in Paoli, Pennsylvania.

Merganser Biotech is a research company that is engaged in the development and licensing of medicines for the treatment of hematological and iron overload diseases that include beta thalassemia and hemochromatosis. The company develops hepcidin mimetic peptides to control iron metabolism and ineffective erythropoiesis. Merganser Biotech was founded 2011 and is based in Newtown Square, Pennsylvania.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

MicroMRI engages in the development and commercialization of medical devices. It involves in the clinical routine bone assessment of bone micro-architecture using magnetic resonance imaging technology. The company offers imaging coils, image post processing software, and biomarker analysis system for radiologists. It also offers contract research services to the pharmaceutical industry, as well as provides guidance and assistance services.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Annovis Bio is specialty pharmaceutical company founded to develop novel treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative disorders. The company has two compounds in clinical development: Posiphen® targets early stage AD and PD and may stop or slow the progression of the disease; BNC targets late stage AD and may stabilize the decline.

Ossianix Inc., a biotherapeutics company, develops single domain antibodies based on VNAR structure from shark. It produces a shark single domain VNAR phage library and has drug discovery programs in various therapeutic areas. Ossianix Inc. has strategic research collaboration with Lundbeck A/S. The company was founded in 2012 and is based in Philadelphia, Pennsylvania with research laboratories in Stevenage, United Kingdom.

Cohero Health offers a proprietary connected health platform for those with respiratory illness. Its sensor-based technology and engaging platform improve medication adherence and care coordination between patients and their care providers. The company offers a suite of tools and technology comprises form flexible inhaler sensors, mobile spirometers, to track real-time adherence and lung function, and a mobile application accessible on iPhone, iWatch, and Android. Cohero Health was founded in 2013 and is headquartered in New York.

Ossianix Inc., a biotherapeutics company, develops single domain antibodies based on VNAR structure from shark. It produces a shark single domain VNAR phage library and has drug discovery programs in various therapeutic areas. Ossianix Inc. has strategic research collaboration with Lundbeck A/S. The company was founded in 2012 and is based in Philadelphia, Pennsylvania with research laboratories in Stevenage, United Kingdom.

Imiplex LLC operates as a biotechnology company that develops protein-based nanotechnology for biosensors, biomaterials, and targeted therapeutic and diagnostic agents. It offers TriPol, a platform that comprises a set of modular components engineered from proteins to provide a flexible system for constructing diverse nanostructures. The company was incorporated in 2003 and is based in Bristol, Pennsylvania.

InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

Ride Health LLC develops a SaaS product platform which enables healthcare providers to schedule, request, and pay for rides on behalf of patients to and from medical appointments. The platform allows coordinators to schedule patient rides in advance or on-demand, sends text message updates and reminders to patients throughout the process, and gives coordinators real-time insight on transportation costs and usage. Ride Health LLC was founded in 2016 and is based in New York, New York.

Galleon Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and markets treatments for sleep apnea and related breathing control disorders. It offers GAL-021, a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients and patients with sleep apnea; GLN- 21,160, an oral development candidate for sleep apnea; and GAL-044, a small molecule used as a preventative medicine for surgical pain. The company was founded in 2003 and is based in Horsham, Pennsylvania.

Neuro Innovations

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

InfraScan, Inc., a medical device company, develops, commercializes, and distributes hand-held diagnostic devices for head injury and stroke assessment based on near-infrared (NIR) technology. It offers Infrascanner, a diagnostic device that enables clinicians to detect intracranial bleeding in patients with head trauma; and education and training services. The company’s device is used in hospital and intensive care monitoring, military, screening in remote areas, sports medicine, pediatrics, ambulance services, and other applications. It sells its products through distributors in North America, South America, Africa, Asia, the Middle East, and Europe. InfraScan, Inc. was incorporated in 2004 and is based in Philadelphia, Pennsylvania with research and development lab in Philadelphia, Pennsylvania.

Enzium is dedicated to developing fluorescent based reagents for highly selective protease activity detection using their proprietary modular protein and dye technology. Their technology allows us to quickly swap out protein modules, much like legos, to easily build new, selective assay reagents. It is their goal to enable their customers to integrate the same reagent kit/assay in applications across entire research, drug, and diagnostic development pipelines.

Bainbridge Health provides hospital systems with a clinical intelligence and data analytics platform to improve medication safety. It provides hospital safety professionals with an infusion pump management software solution to better manage pump data and enhance patient safety. Bainbridge Health also offers a clinician-focused infusion pump management system known as InfusionWare that enables clinicians to manage infusion data in one centralized location.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself. ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Phrase Health, Inc. provides software solutions for health care sector. The company was founded in 2018 and is based in Philadelphia, Pennsylvania.

Acuity Pharmaceuticals is a pharmaceutical company that is focused on the treatment and prevention of ophthalmic diseases. It develops treatments for age-related macular degeneration and diabetic retinopathy. The company offers Cand5, a clinical compound that is able to shut down vascular endothelial growth factor. Acuity Pharmaceuticals was acquired by OPKO Health in June 2011. Acuity Pharmaceuticals was founded in 2007 and is based in Philadelphia, Pennsylvania.

NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Solaris Therapeutics

HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

The Wistar Institute is the nation’s first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research. In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research—a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

TREVENTIS™ Corporation is an early stage biotechnology company focused on diseases associated with protein misfolding such as Alzheimer’s, Parkinson’s and Huntington’s. Currently, the Company has two major areas of discovery and development including: (1) the development of drugs that halt Alzheimer’s disease (and other dementias) progression with the promise of stabilizing or improving cognition and (2) the development of companion diagnostics for detection of AD to allow for early drug intervention to minimize neuronal loss.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

VenatoRx Pharmaceuticals, Inc., a pharmaceutical company, discovers and develops anti-infective agents. The company provides various antibacterial agents. It focuses on addressing resistant hospital and community bacterial infections, including difficult-to-treat infections caused by MRSA, Pseudomonas spp, and Salmonella spp. The company was founded in 2010 and is based in Malvern, Pennsylvania.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Genome Profiling, LLC, a bioinformatics company, engages in the discovery of novel epigenetic biomarkers for treating diagnosing, and predicting chronic and life-threatening diseases. It offers GenPro Analytics, a software platform to discover novel epigenetic biomarkers that scientists and medical professionals use to predict, diagnose, and monitor the likelihood and progression of disease in individuals with more sensitivity, specificity, accuracy, and cost-effectiveness. The company was incorporated in 2012 and is based in Wayne, Pennsylvania.

To prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care.

Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Melior Discovery, Inc. develops an in vivo pharmacology platform that identifies novel indications from pre-clinical and development-stage candidates. The company offers theraTRACE, an indications discovery platform of multiplexed in vivo models that focus on various indications/therapeutic areas, including neurodegenerative disease and psychiatry, inflammation, acute and chronic pain, metabolic disease, gastrointestinal and urology, cardiovascular disease, and dermatology aspects. It serves clients in pharmaceutical and biopharmaceutical industries. The company was founded in 2005 and is based in Exton, Pennsylvania.

Niiki Pharma is a development focused oncology company specializing in first-in-class cancer treatments directed at novel cellular targets and related companion diagnostics. With a team of experts in cancer drug development and commercialization, Niiki Pharma programs are characterized by quality, speed and capital efficient processes.

Pillo, Inc. designs and develops a digital care management platform that provides health care plans for adults with chronic conditions at home. The company offers Pillo, a robot, which enable people to manage their health; answer health and wellness questions; connect with healthcare professionals; manage vitamins and medication; and store, dispense, and order refills when required. The company’s robot also sends notifications to the user when medications are missed; sees and hears user to keep them healthy and safe; and syncs with wearables and smart home devices. Pillo, Inc. was incorporated in 2015 and is based in New York, New York.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Renovacor, Inc., a biopharmaceutical company, develops therapies for the treatment of cardiovascular disease. It develops a gene therapy, which helps to restore cardiac function in patients with heart failure. The company was founded in 2013 and is based in Philadelphia, Pennsylvania.

Oncora Medical, Inc. develops an analytics platform that helps radiation oncologists to use data to provide the care for cancer patients. It provides plug-and-play data extraction tools to integrate clinical information from electronic medical record systems, treatment planning software, and oncology information systems into database; allows physicians to make personalized treatment recommendations for their patients using historical data and predictive analytics; and enables physicians to apply machine learning algorithms to their data to gain information about patient outcomes. Oncora Medical, Inc. was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Olive Devices is an assistive device company developing smart glasses to improve communication for deaf and hard of hearing persons.

Halo Labs Inc. operates as a cannabis cultivation, manufacturing, and distribution company that grows, extracts, and processes cannabis flower, oils, and concentrates. The company also offers edible products in California and Oregon. It serves licensed retailers and wholesalers. Halo Labs Inc. has a strategic partnership with High Tide Inc; and with OG DNA Genetics Inc to develop genetics in Oregon. The company was founded in 2016 and is headquartered in Toronto, Canada.

Hsiri Therapeutics is a development stage pharmaceutical company engaged in the discovery and development of new antibiotics to treat diseases caused by drug resistant bacteria. Hsiri Therapeutics’ efforts are primarily directed at two discrete groups of pathogens – mycobacterial diseases and gram-negative infections. Hsiri Therapetics was formed based on the antibiotic research that originated in the laboratories of Professor Marvin Miller at the University of Notre Dame.

NuPathe Inc., a specialty pharmaceutical company, focuses on the development and commercialization of branded therapeutics for neurological and psychiatric disorders. The company’s lead product is Zecuity, which is a sumatriptan iontophoretic transdermal system used for the acute treatment of migraine with or without aura in adults. Its pipeline product candidates include NP201 for the continuous symptomatic treatment of Parkinson's disease; and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The company develops its products using SmartRelief, a proprietary transdermal medication delivery technology based on iontophoresis, a non-invasive method of actively transporting molecules, such as sumatriptan; and Long-Acting Delivery, a biodegradable polymer matrix, which uses medical polymers and an active drug combined to form a small implant for injection just below the skin. NuPathe Inc. was founded in 2005 and is based in Malvern, Pennsylvania. As of February 20, 2014, NuPathe, Inc. operates as a subsidiary of Teva Pharmaceutical Industries Limited.

Eagle Vision Pharmaceutical Corp. offers a novel, clinical-stage, molecular imaging opportunity that enhances the powerful potential of widely available Magnetic Resonance Imaging (MRI) to revolutionize the diagnosis and management of chronic human disease (“Magnetic PET”). SeeMoreTM (EVP1001), a patented, first-in-class, intravenous, manganese-based, intracellular agent that targets metabolically active cells, capitalizes on the high resolution tissue discrimination of MRI to provide superior diagnostic accuracy and earlier assessment of response to therapy for improved patient management. EVP1001 distinguishes healthy from abnormal tissue in a single, noninvasive exam that avoids radiation and radioactive agents. Preclinical and clinical results have validated the technology for broad applications including evaluation of cancer, chronic liver disease and heart disease. Currently, a world-class medical center is conducting advanced clinical trials using EVP1001 to evaluate stem cell therapy for the heart.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Palvella Therapeutics, Inc., a biopharmaceutical company, develops and commercializes pathogenetically targeted therapies for serious and rare genodermatoses diseases. It offers QTORIN, an anhydrous gel that comprises excipients selected in an optimized ratio to achieve drug stability at room temperature and enable cutaneous distribution into the keratinocytes in the basal layer of the epidermis and to the reticular dermis, where the pathology manifests in various dermatologic conditions. Palvella Therapeutics, Inc. was founded in 2015 and is based in Wayne, Pennsylvania.

Phoenix S&T, Inc. designs, develops, and supplies nanospray and microspray systems for life research and drug discovery solutions. The company’s Nimbus and pneu-Nimbus NanoLC systems provide ionization for LC/MS experiments; clinical diagnostics; and homeland security. It offers column haters, column coolers, and emitters and columns. The company’s products are used in various applications, including proteomics, biomarkers, and direct infusion. It serves customers in Europe and China. The company was founded in 2001 and is based in Chadds Ford, Pennsylvania.

Full Investment Portfolio Money market funds: 3.09% Corporate bonds and note: 18.26% U.S. government and agency securities: 22.92% Municipal bonds: 0.28% Fixed income funds: 0.92% Equity funds and securities: 25.23% Futures contracts: 0.05% Other: 0.11% Commodity funds: 0.48% Multi-strategy hedge funds: 10.64% Private equity: 0.41% Real estate funds: 2.70% Fixed income funds: 2.13% Equity funds: 12.42% Opportunistic funds: 0.13% Investments carried at equity: 0.23% Founded in 1884, Temple University is a non-profit organisation based in the United States which provides higher education to the students.

Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

CarePartners Plus LLC, a healthcare data and information company, provides patient management solutions. It offers Wellby, a patient engagement technology system that helps people in following steps for better health. The company also provides patient engagement, caregiver management, care coordination, and cost containment solutions for hospitals and physician groups. It serves patients and consumers; employers and associations; government agencies; health insurers; hospital and medical groups; public health system centers; accreditation organizations; health care professionals; educators and researchers; and investors. CarePartners Plus LLC was incorporated in 2009 and is based in Horsham .

COOL~BIO is a biotechnology company focused on developing hypothermia-activated biologics. Therapeutic hypothermia (TH) is the process of cooling the body to prevent organ damage and is widely-used in cardiac surgery, ischemic stroke, cardiac arrest, neurosurgery and traumatic brain injury. Their lead molecule is an anti-platelet agent being developed for use during cardiopulmonary bypass.

Immune Control, Inc. was formed in 2001 based on technology developed in the laboratories of Professors Bradford Jameson and Ana Tretiakova, Department of Biochemistry, Drexel University College of Medicine. Initial funding came from Argil Management, LLC, of Boston. In 2003, Stephen Roth, Ph.D., became president and CEO of Immune Control. The Company plans to complete an investigational new drug (IND) application to be submitted to the Food and Drug Agency in 2005. The IND application will propose the use of an already marketed serotonin antagonist in multiple myeloma patients in a small, and relatively short, phase 1/2 clinical trial. If the drug has significant, clinical efficacy against the malignant B cells characteristic of multiple myeloma, they would immediately begin plans for a larger, phase 3 trial. Positive results in the first trial would constitute clinical proof-of-concept for the Company's basic premise-that serotonin antagonists have clinical utility against inappropriately activated immune cells. Another Company goal focuses on proprietary serotonin antagonists that are more potent than those already approved, and that do not cross the blood-brain barrier, making them free of adverse neurological side-effects. Such new chemical entities would be screened for their abilities to bind to specific immunological serotonin receptors, which are now being characterized. The Company has made progress with at least two receptors, one of which has apparently not previously been described. Research on the molecular biology of the receptors is underway at Drexel University College of Medicine, and new chemical entities to be screened for serotonin antagonist activity are being synthesized for the Company. Ultimately, they hope to find compounds that can be used against many hematologic cancers, transplant rejection, and against a host of diseases that are all caused by inappropriate lymphocyte activation. Examples of such diseases are type I diabetes, rheumatoid arthritis, lupus, asthma, and many of the muscular dystrophies. The market size for drugs that treat each of these conditions exceeds a billion dollars. Simultaneously, the Company aggressively protects its intellectual property with patent applications. Novel use applications, novel compound applications, and novel receptor applications are all examples of the Company's existing IP portfolio, which has been licensed exclusively and worldwide to the Company by Drexel University.

Group K Diagnostics, Inc. develops and manufactures a point-of-care diagnostic device for testing liver function. The company offers MultiDiagnostic, a multi-test modular point of care (POC) diagnostic test using paper-based microfluidics which provides three diagnostics with one blood drop. The company also develops a mobile and desktop software that allows patients to upload the picture of the sample card on the application and read the results. Group K Diagnostics, Inc. was founded in 2016 and is based in Philadelphia, Pennsylvania.

Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.

WellTrackONE is a population health management company that offers an end-to-end solution to physician offices, ACOs, integrated delivery networks, hospitals, and other physician networks that helps them administer the Medicare Annual Wellness Visit to all their Medicare patients. The company provides clinical risk management services used to offer a comprehensive baseline report for detailing modifiable risk factors, preventative goals, and measurable data. It was founded in 2012 and headquartered in Hilton Head Island, South Carolina.

Sansrosa Pharmaceutical Development, researches and develops dermatological products for the treatment of rosacea.

Alteris Therapeutics, Inc. engages in the discovery and development of therapeutics and vaccines based on alternative gene splice forms for the treatment of cancer. Its compound, ALT-110, a therapeutic vaccine against the splice variant growth factor EGFRvIII, is currently being tested in a Phase I cancer trial. The company also has a drug discovery program, which targets tumors, including breast, colon, lung, ovarian, and central nervous system cancers. Alteris Therapeutics, formerly known as Spliceomix, Inc., was founded in 2002 and is based in Philadelphia, Pennsylvania. As of October 12, 2005, Alteris Therapeutics Inc. is a subsidiary of Celldex Therapeutics Inc.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Novira Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antiviral drugs for the treatment of chronic hepatitis B infection. It develops core and cccDNA inhibitor anti-HBV drugs. Novira Therapeutics, Inc. was formerly known as Molecmo Nanobiotechnologies, Inc. The company was incorporated in 2006 and is based in Doylestown, Pennsylvania. As of December 4, 2015, Novira Therapeutics, Inc. operates as a subsidiary of Johnson & Johnson.

Immunome is a biotechnology company that specializes in immunotherapy, biotechnology, and antigen discovery. It features a software platform that enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens.

Solaris Therapeutics

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

HealthQX specializes in Value-based Payment (VBP) analytic software solutions for health plans and providers. Its VBP analytics platform, ClarityQx, provides the capabilities to design, implement, and monitor the on-going performance of payment models such as episodic, bundled, or accountable care arrangements. The company was founded in 2012 and is based in King Of Prussia, Pennsylvania.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

Ceptaris Therapeutics, Inc. is a privately held, specialty pharmaceutical company that is developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). If approved, Ceptaris' investigational drug would be the first topical mechlorethamine product available to treat the signs and symptoms of this rare cancer.

Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

Jenrin Discovery, Inc., a pharmaceutical company, develops small molecule drugs and therapeutics targeting peripheral tissues for various chronic diseases. It develops peripherally selective agents in variety of therapeutic areas, such as diabetes, NAFLD/NASH, obesity, autoimmune/inflammatory disorders, and malaria. The company was founded in 2004 and is based in Philadelphia, Pennsylvania.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Marillion Pharmaceuticals Inc. develops and commercializes pharmaceuticals and therapeutics for the treatment of cancers, inflammatory, and autoimmune diseases.